Know Cancer

forgot password

Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Phase 1
18 Years
Open (Enrolling)
Refractory Multiple Myeloma

Thank you

Trial Information

Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma


I. To determine the maximally tolerated doses of dinaciclib and bortezomib, when used in
combination, in two different schedules, for treatment of relapsed multiple myeloma.


I. To determine the toxicities associated with dinaciclib and bortezomib, when used in
combination, for treatment of relapsed multiple myeloma.

II. To determine the overall response rate associated with dinaciclib and bortezomib, when
used in combination, for treatment of relapsed multiple myeloma.

III. To explore the differences in toxicity associated with two different schedules of
dinaciclib and bortezomib used in combination.


I. To examine if expression levels of target cyclin dependent kinase (CDK): CDK 2,5,7 and 9
levels in cluster of differentiation (CD)138-purified tumor cells, will be correlated with
response (clinical and molecular) to determine if high or low level target CDK expression,
if present, influences dinaciclib efficacy.

II. To examine if immunoglobulin (Ig)H translocation status, P53 status and presence of Myc
amplification or rearrangement, determined on patient bone marrow before treatment, using a
pre validated fluorescence in situ hybridization (FISH) panel to identify common myeloma
translocations, will be correlated with molecular and/or clinical markers of drug activity,
and to assess if specific genetic subgroups of myeloma tumors are responsive or resistant.

III. To determine the gene expression profiles of myeloma cells before and after treatment
to understand the role of tumor gene dysregulation and/or dinaciclib induced effects on

OUTLINE: This is a dose escalation study of dinaciclib and bortezomib. Patients are assigned
to 1 of 2 treatment schedules.

SCHEDULE I: Patients receive dinaciclib intravenously (IV) over 2 hours and bortezomib
subcutaneously (SC) on days 1, 8, and 15 and dexamethasone orally (PO) once daily (QD) on
days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease
progression or unacceptable toxicity.

SCHEDULE II: Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1
and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 and 90 days.

Inclusion Criteria:

- Serum creatinine =< 2.5 mg/dL

- Absolute neutrophil count >= 1000/uL

- Untransfused platelet count >= 75000/uL

- Hemoglobin >= 8 g/dL

- Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)

- Patients with relapsed multiple myeloma who have already received one or more
standard treatment regimens

- Measurable disease of multiple myeloma as defined by at least ONE of the following:

- Serum monoclonal protein >= 1 g/dL

- >= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

- Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum
immunoglobulin kappa to lambda free light chain ratio

- Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease) (myeloma
protocols only)

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- Adequate residual organ function per treating physician discretion; Note: there is no
limit with regard to the number of prior therapies

- Provide informed written consent

- Negative pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only

- Willing to provide samples for correlative research purposes

- Willing to return to consenting institution for follow-up during the study

- Recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior
antineoplastic therapy

Exclusion Criteria:

- Any of the following recent therapies:

- Alkylators (e.g. melphalan, cyclophosphamide) =< 14 days prior to registration

- Anthracyclines =< 14 days prior to registration

- High dose corticosteroids, immune modulatory drugs (thalidomide or
lenalidomide), or proteosome inhibitors (bortezomib) =< 7 days prior to

- Concomitant high dose corticosteroids (concurrent use of corticosteroids); EXCEPTION:
patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if
they are being given for disorders other than amyloid, i.e., adrenal insufficiency,
rheumatoid arthritis, etc.

- Other active malignancy =< 2 years prior to registration; EXCEPTIONS: non-melanotic
skin cancer or carcinoma in-situ of the cervix; NOTE: if there is a history of prior
malignancy, they must not be receiving other specific treatment for their cancer

- Any of the following:

- Pregnant women or women of reproductive ability who are unwilling to use 2
effective methods of contraception from the time of signing the informed consent
form through 30 days after the last dose of study drug

- Nursing women

- Men who are unwilling to use a condom (even if they have undergone a prior
vasectomy) while having intercourse with any woman, while taking the drug and
for 30 days after stopping treatment

- Other co-morbidity which would interfere with patient's ability to participate in
trial, e.g. uncontrolled infection, uncompensated heart or lung disease

- Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered
investigational; NOTE: bisphosphonates are considered to be supportive care rather
than therapy, and are thus allowed while on protocol treatment

- Peripheral neuropathy >= grade 2 on clinical examination during the screening period

- Major surgery =< 14 days prior to registration

- Currently taking strong or moderate inhibitors/inducers of cytochrome P450 3A4
(CYP3A4); Note: dinaciclib is a CYP3A4 substrate; patients should not take
grapefruit/grapefruit juice or St. John's Wort; use of strong or moderate CYP3A4
inhibitors or CYP3A4 inducers is prohibited from =< 7 days prior to registration

- Any of the following conditions:

- Myocardial infarction =< 6 months prior to registration or has New York Heart
Association (NYHA) class III or IV heart failure

- Uncontrolled angina

- Severe uncontrolled ventricular arrhythmias

- Electrocardiographic evidence of acute ischemia

- Active conduction system abnormalities; NOTE: prior to study entry, any
electrocardiogram (ECG) abnormality at screening must be documented by the
investigator as not medically relevant

- Known hypersensitivity to bortezomib, boron, or mannitol

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study per the judgment of the treating physician

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of dinaciclib and bortezomib when given together with dexamethasone, based on incidence of dose-limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Outcome Description:

MTD is defined as the dose level below the lowest dose that induces DLT in at least one-third of patients.

Outcome Time Frame:

Course 1 (up to 28 days)

Safety Issue:


Principal Investigator

Shaji Kumar

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

December 2012

Completion Date:

Related Keywords:

  • Refractory Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Mayo Clinic Rochester, Minnesota  55905
Mayo Clinic in Arizona Scottsdale, Arizona  85259-5404
Mayo Clinic in Florida Jacksonville, Florida  32224
M D Anderson Cancer Center Houston, Texas  77030
University of Wisconsin Cancer Center Riverview Wisconsin Rapids, Wisconsin  54494